Publications

All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings.

KHAN, PY; Franke, MF; Hewison, C; Seung, KJ; Huerga, H; Atwood, S; Ahmed, S; Khan, M; Sultana, T; Manzur-Ul-Alam, M; Vo, LN Q; Lecca, L; Yae, K; Kozhabekov, S; Tamirat, M; Gelin, A; Vilbrun, SC; Kikvidze, M; Faqirzai, J; Kadyrov, A; Skrahina, A; Mesic, A; Avagyan, N; Bastard, M; Rich, ML; ... Mitnick, CD.

2022

The European respiratory journal, (2022).59 1 10.1183/13993003.04345-2020.

More treatment options for rifampicin-resistant tuberculosis: the role of economic evaluation in informing uptake.

SWEENEY, S; SINGH, MP;

2022

The Lancet Global Health, (2022).11 2 10.1016/S2214-109X(22)00519-8.

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial.

Wallis, RS; Ginindza, S; Beattie, T; Arjun, N; Likoti, M; Sebe, M; Edward, VA; Rassool, M; Ahmed, K; FIELDING, K; Ahidjo, BA; Vangu, MD T; Churchyard, G;

2022

PloS One, (2022).17 2 10.1371/journal.pone.0252097.

ISIDLSHTM/Model_Size_Selection.

BENEST, J; Rhodes, S; Evans, TG; WHITE, RG;

2022

, Github (2022).

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuber...

Berry, C; Du Cros, P; FIELDING, K; Gajewski, S; Kazounis, E; McHugh, TD; Merle, C; Motta, I; MOORE, DA J; NYANG'WA, B-T;

2022

Trials, (2022).23 1 10.1186/s13063-022-06331-8.

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.

NYANG'WA, B-T; Berry, C; Kazounis, E; Motta, I; Parpieva, N; Tigay, Z; Solodovnikova, V; Liverko, I; Moodliar, R; DODD, M; Ngubane, N; Rassool, M; McHugh, TD; Spigelman, M; MOORE, DA J; Ritmeijer, K; Du Cros, P; FIELDING, K; TB-PRACTECAL Study Collaborators,;

2022

New England Journal of Medicine, (2022).387 25 10.1056/NEJMoa2117166.

A modified decision tree approach to improve the prediction and mutation discovery for drug resistance in Mycobacterium tuberculosis.

Deelder, W; Napier, G; CAMPINO, S; Palla, L; PHELAN, J; CLARK, TG;

2022

BMC genomics, (2022).23 1 10.1186/s12864-022-08291-4.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modelling study.

Portnoy, A; Clark, R; Quaife, M; WEERASURIYA, C; Mukandavire, C; Bakker, R; Deol, A; Malhotra, S; Gebreselassie, N; Zignol, M; Sim, SY; Hutubessy, RC W; Baena, IG; Nishikiori, N; JIT, M; WHITE, R; Menzies, N;

2022

medRxiv (2022). 10.1101/2022.05.04.22274654.

Evaluation of three alternatives cost-effective culture media for Mycobacterium tuberculosis detection and drug susceptibility determination using the microscopic observation drug susceptibility (MODS) assay.

Rodriguez, J; Alcántara, R; Rodríguez, J; Vargas, J; Roncal, E; Antiparra, R; Gilman, RH; Grandjean, L; MOORE, D; Zimic, M; Sheen, P;

2022

Tuberculosis (Edinburgh, Scotland), (2022).137, 10.1016/j.tube.2022.102273.

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.

SWEENEY, S; Berry, C; Kazounis, E; Motta, I; VASSALL, A; DODD, M; Fielding, K; NYANG'WA, B-T;

2022

PLOS Global Public Health, (2022).2 12 10.1371/journal.pgph.0001337.